Welcome on the ovarian cancer study portal!
Find current studies on ovarian, fallopian tube and peritoneal cancer
Studies improve opportunities
Studies and surveys are important elements in improving the treatment procedures and quality of life for women affected by ovarian, fallopian tube and peritoneal cancer in the future. The ovarian cancer study portal is intended to provide you with a complete overview of all current studies offered by the major German study groups NOGGO and AGO for this specific gynecological tumor disease in Germany.
Aims of the study portal
Here we offer you comprehensive information on the objectives, procedures and framework conditions of current studies or surveys, as well as where these studies are being conducted by study centers, clinics or practices in your area. The German Ovarian Cancer Foundation, together with the initiators Prof. Dr. med. Phillip Harter (Klinik Essen-Mitte) and Prof. Dr. med. Jalid Sehouli (Charité Berlin), has launched this innovative information portal.
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationProf. Dr. med. Jalid Sehouli
Director of the Clinic for Gynaecology with Center for Oncological Surgery (CVK) and Clinic for Gynaecology (CBF)
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationAbout the founding of the ovarian cancer study portal
Dr. Phillip Harter and Prof. Dr. Sehouli in conversation
Partners of the ovarian cancer study portal
Long-standing cooperation partners
Supporters of the ovarian cancer study portal
Professional and transparent
The German Ovarian Cancer Foundation works together with the supporters of the study portal to improve studies and surveys. This would not be possible without the high-quality and professional research work of the study centers and the research-based pharmaceutical industry. We at the German Ovarian Cancer Foundation and on behalf of the GYN study portal would like to take this opportunity to thank our supporters.
